高级检索
    杨梅, 沈博. IMpassion130研究: 阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌的疗效分析[J]. 循证医学, 2021, 21(2): 71-75. DOI: 10.12019/j.issn.1671-5144.2021.02.002
    引用本文: 杨梅, 沈博. IMpassion130研究: 阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌的疗效分析[J]. 循证医学, 2021, 21(2): 71-75. DOI: 10.12019/j.issn.1671-5144.2021.02.002
    shu
    YANG Mei, SHEN Bo. IMpassion130: The Efficacy of Atezolizumab Plus Nab-Paclitaxel Treatment in Comparison With Nab-Paclitaxel Alone as First-Line Treatment of Advanced Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 71-75. DOI: 10.12019/j.issn.1671-5144.2021.02.002
    Citation: YANG Mei, SHEN Bo. IMpassion130: The Efficacy of Atezolizumab Plus Nab-Paclitaxel Treatment in Comparison With Nab-Paclitaxel Alone as First-Line Treatment of Advanced Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 71-75. DOI: 10.12019/j.issn.1671-5144.2021.02.002
    shu

    IMpassion130研究: 阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌的疗效分析

    IMpassion130: The Efficacy of Atezolizumab Plus Nab-Paclitaxel Treatment in Comparison With Nab-Paclitaxel Alone as First-Line Treatment of Advanced Triple-Negative Breast Cancer

      摘要
      • HTML全文
      • 参考文献(7)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回